Cargando…
Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS). Herein, we report three SPMS patients presenting disease reactivation in the first three months after switching f...
Autores principales: | Abbadessa, Gianmarco, Maida, Elisabetta, Miele, Giuseppina, Bile, Floriana, Lavorgna, Luigi, Bonavita, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605018/ https://www.ncbi.nlm.nih.gov/pubmed/36294354 http://dx.doi.org/10.3390/jcm11206033 |
Ejemplares similares
-
Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023) -
Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic
por: Sparaco, Maddalena, et al.
Publicado: (2022) -
Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
por: Senzaki, Kensuke, et al.
Publicado: (2021) -
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023) -
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)